Hypocrellin A (HA), a perihydroxylated polycyclic quinone isolated from the fungus of Shiraia bambusicola, exhibits a wide spectrum of biological activities in pre-clinical studies. However, poor water solubility is a major clinical constraint factor of HA, leading to unpredictable bioavailability. In this study, HA-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (PLGA/HA NPs) were prepared by the single-emulsion solvent-evaporation technique. Characterization of PLGA/HA NPs showed that HA was successfully encapsulated on the PLGA. The drug-loading content and encapsulation efficiency (EE) were 7.0% and 57.5%, respectively. The in vitro release profile demonstrated that HA was released more slowly from nanoparticles in pH 1.5 and pH 6.8 than in pH 7.4. Furthermore, the highest solubility of PLGA/HA NPs in aqueous solution was approximately 35.67-fold that of native HA (n-HA). PLGA/HA NPs had more superior stability compared with n-HA in physiological conditions. In this paper, a sample and sensitive LC-MS/MS method was validated for the first time to quantify HA in rat plasma. The pharmacokinetic parameters and bioavailability of HA between PLGA/HA NPs and n-HA were compared after oral administration in rat. The results implied that the relative bioavailability of PLGA/HA NPs was 2.67-fold that of n-HA, and PLGA/HA NPs had a longer half-life. Therefore, these results suggested that PLGAblend nanoparticles improved the solubility, stability and bioavailability of HA, and could become a potential and promising carrier for the oral delivery of HA.
Introduction
Hypocrellin A (HA), an active compound isolated from Shiraia bambusicola that mainly grows in China and Japan, is a novel photosensitizer of high singlet oxygen quantum yield for photodynamic therapy (PDT).
1-3 HA has many biological and pharmacological properties, such as antitumour, 2,4,5 antiviral, 6 antibacterial, and antileishmanial activities. 7, 8 The most effective activity of HA is anticancer, which can decrease A549 cell viability via PDT induced cell apoptosis. 4 Moreover, it possesses excellent photodynamic antimicrobial activity. 8 These ndings suggested that HA may be used to treat various diseases. Thus far, HA has been almost wholly utilized as an external formulation for skin diseases such as white lesions of the vulva, vitiligo, tinea capitis, psoriasis and lichen amyloidosis. 9 However, little information is currently available on the characterization of its pharmacokinetic properties; this information is necessary and helpful to develop new clinical HA preparations for oral and intravenous administration.
In addition, HA is a hydrophobic drug, and its solubility must be improved to maximize its potential bioavailability.
10
One strategy to improve HA solubility is chemical modication. Typical chemical modication techniques included attempted salt formation, complexed with metal ions, and added cosolvents, hydrotropic agents and surfactants. These approaches increase solubility by altering a solvating environment, making it better suited for maintaining hydrophobic solutes in aqueous solution.
11 Indeed, several research approaches have been reported to enhance HA solubility, including sulfonation of HA 12 and chelation of HA with metal ions. 13, 14 However, most of the HA derivatives generated to date have exhibited less PDT efficacy than their parent; those water-soluble derivatives reduced cellular uptake and led to poor photodynamic activity in vitro, storage stability and biocompatibility. 15 In recent years, nano drug delivery systems (NDDS) have provided remarkable advantages in enhancing water solubility and pharmacological activity of photosensitizers.
16-20
As a biodegradable polymers, PLGA has been extensively used in NDDS for lower toxicity and excellent loaded-drug efficacy. 17, 19, 20 PLGA improved loaded drugs the dispersibility, solubility, and absorption in vitro, and prolonged the half-life time and plasma circulation in vivo of loaded drugs. 19, 21 In addition, PLGA is degraded in the body into nontoxic lactic acid and glycolic acid, which are the normal components of Kreb's cycle, and subsequently eliminated as carbon dioxide and water without affecting the normal cellular functions. 22 In previous work, we reported that HA-loaded PLGA nanoparticles (PLGA/HA NPs) improved the photodynamic anticancer effect. 4 However, developed nanoparticle formulations need a thorough evaluation in terms of pharmacokinetic investigation. In fact, the physicochemical parameters of nanoparticles, such as particle size, hydrophobicity and surface modication, dramatically changed drug pharmacokinetics and impacted drug bioavailability and biodistribution. 19 On the basis of these factors, in the present study, we further explored the in vitro release, solubility and stability of PLGA/HA NPs. Moreover, a sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method with multiple reaction monitoring (MRM) was developed for the rst time and validated for the determination of HA in rat plasma. Finally, we compared the pharmacokinetic parameters and bioavailability of HA between PLGA/HA NPs and n-HA aer oral administration in rat.
Materials and methods

Chemicals
HA (98%) was isolated from the bodies of Shiraia bambusicola. Docetaxel (99.8%) was obtained from Aladdin Industrial Corporation (Shanghai, China). Poly (D,L-lactic-co-glycolic acid) (PLGA, L/G ¼ 50/50, M W ¼ 30 kDa) was obtained from Ji Nan Dai Gang Biomaterial Corporation (Shandong, China). Polyvinyl alcohol (PVA, M W ¼ 31 kDa) and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich (MO, USA). Pepsin (1 : 3000) and trypsin (1 : 250) were obtained from Solarbio Corporation (Beijing, China). Spectramax M2 Multiscan Spectrum was obtained from Molecular Devices Corporation (USA). Methanol and acetonitrile (HPLC grade) were purchased from Tedia Company (USA). HPLC-grade water produced by MilliQ System (Millipore, Paris, France) was utilized throughout the experiments. All other chemicals were of analytical grade and commercially available.
Preparation of PLGA/HA NPs
PLGA/HA NPs were obtained using the single-emulsion solventevaporation technique previously reported by our group. Briey, HA (10 mg) and PLGA (100 mg) were dissolved in acetone (2.5 mL) for 6 h at room temperature. The organic phase was rapidly injected into 50 mL PVA aqueous solution (0.5%, w/v) and homogenized using a high-speed homogenizer (IKA, Germany), resulting in an oil-in-water (O/W) solution. Next, the residual organic solvent was eliminated by mechanical stirring at 1500 rpm overnight. The particles were then recovered by centrifugation (Eppendorf Centrifuge 5418R, Germany) at 13 500 rpm for 30 min at 4 C, and washed twice with distilled water to remove the residual drugs and emulsiers. Lastly, PLGA/HA NPs were added 2% sucrose as a freeze-dried adjuvant agent to avoid aggregation; PLGA/HA NPs were freeze-dried at À80 C for 48 h and stored at À20 C in the dark before use. 
Drug loading efficiency (LE) and encapsulation efficiency (EE)
Animal
Sprague-Dawley rats were kept in an environmentally controlled breeding room and fed with standard laboratory food and water for two weeks before starting the experiments. The experimental protocol were conformed to the principles of the National Institutes of Health guide for the care and use of Laboratory Animals, (NIH publications no. 8023, revised 1978) and approved by the Animal Care and Institutional Animal Ethics Committee of Nanjing Normal University.
Chromatograph system and conditions for HA quantication
The LC-MS/MS analysis was conducted in positive ion ESI mode on a Waters Quattro Micro System equipped with a triplequadrupole mass spectrometer connected to a liquid chromatograph (Waters Alliance). Chromatographic separation was performed on an Agilent Zorbax Extend-C 18 column (4.6 Â 150 mm, 5 mm; Agilent Technologies, Waldbronn, Germany). The column temperature was maintained at 28 C. 23 The mobile phase consisted of methanol (A), and water containing 0.1% formic acid (B) (90 : 10 v/v) was used for isocratic elution at 1 mL min À1 , with a total run time per sample of approximately 5 min. The injection volume was 10 mL. Mass spectrometric detection was performed on a Waters Quattro Micro triple-quadrupole mass spectrometer equipped with an electrospray ionization (ESI) interface. Both the analyte HA and internal standard (IS) docetaxcel were monitored under positive ion-multiple reaction monitoring (+MRM) mode with transitions of m/z 547.1 / 529 for HA, and m/z 830.7 / 549.4 for IS, respectively. Other parameters of the mass spectrometer were as follows: spray voltage, 3250 V; vaporizer temperature, 300 C; and capillary temperature, 350 C. Argon was used as the collision gas for collision-induced dissociation (CID), 3.2 Â 10 À3 mbar; solvent off gas ow rate, 400 L h À1 ; and gas curtain gas velocity, 50 L h À1 . The auto sampler cooler was maintained at 4 C.
The data were acquired and processed using Analyst version MassLynx soware (Version 4.0). For quantication, the peak area ratios of the target ions of the HA were compared to those of the IS with weighted 1/X 2 (where X ¼ drug concentration) least squares calibration curves in which the peak area ratios of the calibration standards were plotted versus their concentrations.
Preparation of stock, standard and quality control samples
Stock solutions of HA (100 mg mL À1 ) and IS docetaxel (500 mg mL À1 ) were dissolved in methanol. The IS working solution was diluted with methanol to 2.5 mg mL À1 . Standard solutions of HA in rat plasma were prepared by spiking with an appropriate volume of the serially diluted stock solutions, giving nal concentrations of 15, 50, 100, 200, 500, 1 000, 1 500, and 2000 ng mL À1 for HA.
Quality control (QC) samples were prepared from blank plasma at high, medium and low concentrations of 1 500, 500, and 50 ng mL À1 , respectively. All solutions were stored at À20 C prior to analysis. In addition, all the samples containing the calibration samples, QC samples and plasma samples were processed and prepared according to the procedure described as follows.
Plasma sample preparation
The 100 mL of heparinized plasma sample (or containing 10 mL HA blank plasma) was aliquoted into a 1.5 mL polypropylene tube and mixed with 10 mL IS solution (2.5 mg mL À1 ) and 50 mL acetic acid. Then, 500 mL of acetonitrile was added, and the solution was vortexed for 5 min. Next, the solution was ultrasonically mixed for 10 min and then centrifuged at 16 000 rpm for 10 min. Aer centrifugation, 400 mL of the supernatant was transferred to a clean vial and dried with concentrator plus (Eppendorf 5305, Germany). The residue was re-dissolved with 100 mL methanol: H 2 O (50 : 50, v/v), and a 10 mL aliquot of the sample was injected into LC-MS/MS for analysis.
Method validation
Methods were validated for specicity, linearity and sensitivity, accuracy and precision, extraction recovery and matrix effect according to the US Food and Drug Administration (FDA) guidance. 2.10.1 Specicity. The specicity of the method was evaluated by comparing the chromatograms of blank plasma from six different rats with the corresponding plasma samples spiked with HA and IS, as well as real samples collected from treated rats aer intravenous (i.v.) administration for 5 min.
2.10.2 Linearity and sensitivity. Calibration curves were constructed by plotting the peak-area ratio of HA to the IS versus the concentrations of the analytes. It was achieved from eightpoint calibration curves covering a concentration range from 15 to 2000 ng mL À1 HA in plasma samples, using a weighted least-squares linear regression (the weighting factor, 1/X 2 ). The lower limit of quantication (LLOQ) was determined based on at least 10 times the signal-to-noise ratio at which the precision (expressed by relative standard deviation, RSD) and accuracy (calculated by relative error, RE) were lower than 20%. 2.10.3 Accuracy and precision. The intra-day accuracy and precision were investigated by determining six replicates of high, medium and low QC samples at concentrations of 1 500, 500 and 50 ng mL À1 on the same day. The inter-day accuracy and precision were studied by determining three levels of QC samples on three consecutive days. The accuracy calculated as follows (4):
2.10.4 Extraction recovery and matrix effect. Extraction recovery of HA was determined by comparing the peak area of the HA spiked and extracted from blank plasma with those of extracted blank plasma spiked with the HA at the same concentration levels. Recoveries were determined at three QC concentrations for plasma (n ¼ 6). Matrix effects were calculated by the mean peak area ratios of blank plasma samples spiked with HA aer extraction divided by the injected working solution with HA at the same QC concentrations. The extraction recovery (5), matrix effects calculated as follows (6):
Extraction recoveryð%Þ ¼ mean peak area of extracted samples mean peak area of un-extracted samples Â 100
Matrix effectð%Þ ¼ mean peak area of un-extracted samples mean peak area in neat standard solutions Â 100 (6) 2.10.5 Stability. The stability of HA was tested by analysing six replicates of HA plasma samples at three QC concentrations under different conditions: 6 h exposure at room temperature, three freeze-thaw cycles at À20 C, and one week storage at À20 C. The stock solution stability of the HA was evaluated using three QC levels samples against freshly spiked solutions.
If assay values were within acceptable limits of accuracy (AE15% RE) and precision (#15% RSD), samples were considered stable.
Pharmacokinetic study of HA and PLGA/HA NPs in rat
Eighteen Sprague-Dawley rats (male and female) with body weight of 200-220 g were divided into three groups (n ¼ 6). The rst group was i.v. administered n-HA (4 mg kg À1 ) in 5% glucose aqueous solution, the second group was orally administered n-HA (40 mg kg
À1
) prepared in 0.5% carboxymethyl cellulose sodium (CMC-Na) to form a suspension, and the third group was orally administered PLGA/HA NPs (containing HA 12.5 mg kg À1 ) in aqueous solution. All rats were fasted overnight before drug administration. Blood samples (300 mL) were drawn from the orbital vein into heparinized centrifuge tubes under anaesthesia at 0.0833 (only for rst group), 0.25, 0.5, 1, 2, 
Results and discussion
Preparation of PLGA/HA NPs
In our study, PLGA/HA NPs were prepared by emulsion solvent evaporation technique. As the linker in PLGA/HA NPs, PVA is a widely used stabilizer for PLGA polymers. The particle size of these nanoparticles was within the range of 20-200 nm reported by Qi et al. 4 The drug loading content of the nanoparticles was 7.0%, and encapsulation efficiency of the nanoparticles was 57.5%. These characteristics did not differ signicantly from previous experimental results. Particle size, loading and encapsulation efficiency inuenced drug solubility, stability and dispersibility. Moreover, properties of PLGA, including concentration, molecular weight, and volume ratio, were related to drug delivery system. 24 
In vitro release prole
Several mechanisms were reported that were responsible for the drug release from the nanoparticles, including surface and bulk erosion, desorption and diffusion. 25 Most of the drug-loaded nanoparticles presented a biphasic release pattern: there was an initial burst release followed by a sustained release of the drug. However, low molecular weight PLGA NPs have also been reported to exhibit a zero-order release prole, particularly with hydrophobic drug molecules. 26 In our study, the dialysis bag diffusion technique was used to study the in vitro drug release of HA from PLGA/HA NPs in articial gastric (pH 1.5), intestinal (pH 6.8) and blood (pH 7.4) biological conditions over a period of 144 h at 37 C. The cumulative percentage release of HA from PLGA/HA NPs is depicted in Fig. 1 . The in vitro drug release kinetics showed a biphasic release only in pH 7.4, with a fast rate of HA release to 29.3% within the initial 3 h. However, we observed that HA release in pH 1.5 and pH 6.8 exhibited zeroorder release proles. HA release was sustained in pH 1.5, pH 6.8 and pH 7.4 to a total of approximately 4.7%, 18.8% and 45%, respectively. At the early stage, the rapid release rate of HA from the nanoparticles may be due to partial absorption or precipitation on the surface of the nanoparticles. Later, HA showed a sustained slow release rate that mainly because diffuse from being encapsulated in nanoparticles.
Solubility and stability study
To investigate the solubility of HA and PLGA/HA NPs, samples were dissolved in double distilled water, forming a supersaturated solution. The results in Fig. 2 showed that the dissolved PLGA/HA NPs formed a red aqueous solution, while the n-HA was hydrophobic and hardly dissolved in aqueous solution, with a slightly visible soluble compound. The PLGA/HA NPs aqueous solution dissolved much more than did n-HA. The highest solubility of PLGA/HA NPs and n-HA was 643 mg mL À1 and 18.03 mg mL À1 , respectively. The solubility of PLGA/HA NPs in aqueous solution was approximately 35.67-fold that of n-HA. In general, poorly water-soluble drugs oen show low bioavailability when administered orally, because the absorption of the drugs in the gastrointestinal tract can usually be a rate-limiting step. 27 Therefore, it is important to enhance drug solubility for improved bioavailability. PLGA could increase the drug solubility and adhesion by forming the stable and amorphous nanoparticles to eliminating the oversaturation of the difference between the particle size of nanoparticles.
11,27 Moreover, PLGA polymer was commonly used to develop smaller particles with narrow poly dispersity. 28 We used PLGA as the nano-carrier because it could distinctly encapsulate drugs into the pore of PLGA to increase hydrophobic drug water solubility. Instability and degradability of drug molecules in physiological pH conditions hindered drug delivery to target tissue. 29 To study the stability properties of HA, n-HA and PLGA/HA NPs were incubated in articial gastric (pH 1.5), intestinal (pH 6.8) and blood (pH 7.4) media. As shown in Fig. 3 , HA was stable in pH 1.5 with the change of time, but rapid degradation of n-HA occurred in physiological pH 6.8 and pH 7.4. Nevertheless, PLGA/HA NPs were more stable under the same conditions, especially under pH 1.5. Consequently, as a drug carrier, PLGA improved the stability of HA in physiological pH conditions. PLGA protected the encapsulated HA against enzymatic and hydrolytic biodegradation, thereby preventing HA from breaking down from the gastrointestinal acid. 30, 31 3.4 Method development 3.4.1 Selection of IS. In LC-MS/MS analysis, it is important to select a suitable compound for the analyte and serve as an internal standard. Four types of compounds were investigated: 1,8-dihydroxy anthraquinone, lafutidine, p-hydroxy benzoic acid butyl ester and docetaxel. However, 1,8-dihydroxy anthraquinone, lafutidine, p-hydroxy benzoic acid butyl ester presented low recovery in plasma compared to HA with the same plasma preparation methods. In our study, docetaxel is a stable and commercialized compound with similar mass spectrometric, chromatographic condition and extraction recovery as HA. Thus, docetaxel is the best selection of IS for HA, and it is helpful when a signicant matrix effect appeared.
3.4.2 Optimization of the mass condition and chromatographic condition. Given that rat plasma is a complex matrix, a sensitive and stable LC-MS/MS condition was rst optimized to quantify HA in plasma samples. First, the standard solution of HA and the IS were injected into the mass spectrometer. The ionization of HA and IS in positive ion and negative ion modes was performed on an ESI ion source and compared in terms of the intensity of produced ions. Finally, HA and IS were analysed in positive ion mode, for the intensity was stronger. In addition, the MRM mode was selected for its better sensitivity and specicity relative to the single ion monitoring (SIM) mode. Thus, the parameters of MS/MS were optimized for the two MRM transitions of m/z 547.1 / 529 for HA Fig. (4A) , and m/z 830.7 / 549.4 for IS Fig. (4B) , respectively. The satisfactory resolution of HA and IS was achieved with methanol and water containing 0.1% formic acid (90 : 10 v/v) with gradient elution at ow rate of 1.0 mL min À1 on an Agilent Zorbax Extend-C18 column (4.6 Â 150 mm, 5 mm). Under the present chromatographic condition, the run time of each sample was 5 min, and the retention time was 3.38 min, 1.78 min for HA and IS, respectively.
Sample preparation.
To attain clean samples with elimination of endogenous interferences, different extraction procedures were conducted, such as solid phase extraction (SPE), liquid-liquid extraction (LLE) and protein precipitation (PP). The SPE method and LLE method were evaluated for extraction of HA and IS, and undeniably produced the cleanest extracts with high sensitivity, but resulted in lower extraction recovery of HA. However, the PP method was the fastest and simplest method resulting in a clean extract. The PP method also resulted in the high extraction recovery of HA and IS. Acetonitrile was adopted for sample preparation because it offered lower background noise and favourable separation. Indeed, acetic acid was also tested to achieve the maximum recovery of HA. In our study, 10, 20, 30, 40, and 50 mL of acetic acid were tested. Finally, an acetic acid volume of 50 mL was the best selection for HA and IS recovery.
Method validation
3.5.1 Specicity. The specicity study aimed to investigate whether endogenous substances in plasma would interfere with the analysis of HA and IS. As shown in Fig. 5 , this test included a blank plasma sample (Fig. 5A) , plasma containing HA and IS Fig. 3 The stability of n-HA (A) and PLGA/HA NPs (B) in artificial gastric (pH 1.5), intestinal (pH 6.8) and blood (pH 7.4) biological condition at 37 C (mean AE S.D., n ¼ 3). ( Fig. 5B) , and a plasma sample obtained aer i.v. administration for 5 min (Fig. 5C) . The results suggested that no endogenous constituents were eluted at the retention time of HA (3.48 min) or IS (1.78 min), and the total run time was 5 min. 3.5.2 Linearity and sensitivity. In the current analytical method, the calibration curves contained eight points, covering a concentration range from 15 to 2000 ng mL
À1
, in rat plasma with correlation coefficient R 2 > 0.9986 for HA. The LLOQ (signalto-noise ratio > 10) of HA in this method was 10 ng mL À1 . 3.5.3 Accuracy and precision. The intra-day and the interday accuracy and precision date of HA in biological matrices are presented in Table 1 . The intra-day and the inter-day precision (RSD, %) values were #10.5% and #15%, respectively. The intra-day and the inter-day accuracy (%) values were in the range of 93.27-98.87% and 94.6-98.87%, respectively. All these results indicated that the method was reproducible and reliable for the determination of HA in rat plasma.
3.5.4 Extraction recovery and matrix effect. The extraction recovery and matrix effect results of HA are summarized in Table 1 . The extraction recovery of HA from low, medium, and high QC samples was in the range from 102 AE 0.28 to 110 AE 0.15%. The matrix effect of HA was from 95 AE 0.05 to 99.5 AE 0.22%, which was considered negligible or insignicant matrix effects.
3.5.5 Stability. The stability of HA in plasma was evaluated under different conditions (short-term, freeze/thaw, long term stability). The results are shown in Table 2 . HA was stable in rat plasma and processed samples under different storage conditions.
Pharmacokinetic study
The validated LC-MS/MS method was rst applied to the pharmacokinetic study of HA in plasma aer oral administration (40 mg kg À1 ) of n-HA (rst group), i.v. administration (4 mg kg À1 ) of n-HA (second group) and oral administration Table 3 . The plasma concentration of the rst group and the third group were determined in 48 h, while the second group could not be determined aer 12 h. The maximum concentration (C max ) of the three groups was 110. Recently, PLGA drug delivery systems were developed to offer important advantages in the bioavailability of drugs. In our study, the terminal elimination half-life (t 1/2b ) and bioavailability of the three groups differed signicantly. The t 1/2b of the three groups was 6.649 AE 0.0058, 2.564 AE 0.0943 and 18 AE 0.303 h, respectively. The results showed that PLGA/HA NPs had low clearance and long half-life compared with n-HA in rat. PLGA/HA NPs prolonged the absorption phase and decreased the distribution, metabolism and obvious controlled release of HA from the nanoparticles. However, this nding was not consistent with previous results. Gu et al. reported HAliposome t 1/2b was 9.85 h.
1 Pharmacokinetic parameters were altered depending upon the carriers and animal models. In addition, PLGA is frequently used for drug carriers because it may increase the residency time of the sustained release formulation and enhance the drug absorption due to intimacy of contact with the epithelium cells. 21 To date, few studies have reported the bioavailability of HA; only the pharmacokinetic parameters of hypericin, which has an analogue structure of HA, was reported. A study by Schulz et al. showed the poor solubility and bioavailability of hypericin. 32 In our study, the results demonstrated that PLGA used for HA delivery by oral administration increased HA bioavailability. Therefore, PLGA could potentially be applied to increase the bioavailability of other hydrophobic compounds.
According to experiment results, PLGA contributed to the improved solubility of HA and facilitated HA transport in vivo. In Table 1 Precision, accuracy, extraction recovery and matrix effect for HA in rat plasma (n ¼ 3) , and PLGA/HA NPs after oral administration of 12.5 mg kg À1 (n ¼ 6).
Concentration
addition, PLGA protected HA from degradation under physiological conditions and enhanced its stability. All of these advantages favoured improved HA bioavailability. Because of the strong attraction of the particles to the negatively charged mucosa of the intestine responsible for a longer residence time in the intestine, mucoadhesive nanoparticles improve the bioavailability of poorly absorbed drugs. 33 Nanoparticles have a plethora of advantages over other delivery systems, including the ability to protect drugs from gastrointestinal degradation, prolong systemic circulation, reduce fed/fasted variable absorption, and control drug release. 34 Therefore, it is expected that with all the aforementioned advantages, the bioavailability of orally delivered drugs in nano form will be improved. However, the mechanism by which PLGA/HA NPs improved HA bioavailability was not detected, and further research is necessary.
Conclusions
In our study, PLGA/HA NPs have been successfully prepared. PLGA/HA NPs had superior solubility and stability compared with n-HA in physiological conditions. In pharmacokinetic study, a rapid, specic, selective, and reproducible LC-MS/MS method was rst developed and validated for the determination of HA in rat plasma. The method was successfully applied to analyse plasma drug concentrations following oral administration of n-HA, PLGA/HA NPs and i.v. administration of n-HA. The pharmacokinetic parameters revealed that PLGA/HA NPs enhanced bioavailability of HA and prolonged HA systemic circulation. Moreover, the improved water solubility of HA was the main reason for its increased bioavailability. Conclusively, encapsulating hydrophobic HA on PLGA polymer will become a promising method for enhanced HA solubility, stability and improved bioavailability.
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